Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 6, 2004. The report primarily details changes in directors' interests in the company's Ordinary Shares and announces share repurchase activities conducted in accordance with shareholder authority granted at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to specific share transactions:
- Share Repurchase (April 30, 2004): 1,010,000 shares purchased for cancellation at 1,184.57 pence per share.
- Share Repurchase (May 5, 2004): 840,000 shares purchased for cancellation at 1,190.54 pence per share.
- US Retirement Plan ADRs: Fund holdings fluctuated between 18,730,717 and 18,794,940 ADRs with average transaction prices of $42.10 and $41.45.
- Employee Plan Share Purchases: Shares purchased for employee plans at prices of £11.6575 and £11.66.
Material Changes
The filing reports specific changes in share ownership and capital structure rather than operational performance changes:
- Share Capital Reduction: A total of 1,850,000 Ordinary Shares were purchased for cancellation during late April and early May 2004.
- Directors' Interests: Multiple transactions occurred involving the GlaxoSmithKline Employee Trust, the SmithKline Beecham Employee Share Option Plan 1991, the US Retirement Savings Plan, and the SmithKline Beecham Employee Benefit Trust. These involved transfers of shares to participants and reinvestment of dividends.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, or contingencies. The document is strictly a regulatory disclosure of director interests and share buyback execution.
Key Facts for Investor Verification
- Verify the total number of shares repurchased for cancellation (1,850,000) and the weighted average price paid.
- Confirm the impact of these repurchases on the company's total outstanding share count.
- Review the specific directors (Dr J-P Garnier, Dr T Yamada, Mr J D Coombe) identified as having interests in the various employee trusts and plans.
- Note that this filing contains no operational or financial performance data for the period.